While numerous studies have demonstrated DNMT inhibitors to promote type I IFN activation and increase tumor response to anti-CTLA therapeutics through cytosolic antiviral double-stranded RNA (dsRNA)-sensing pathways, the full spectrum on how chromatin regulators can modulate tumor immunity and immunotherapy in breast cancer is still poorly understood. The gene discussed is DNMT1; the disease is neoplasm.